How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
Perini, Guilherme Fleury; Fischer, Thais; Gaiolla, Rafael Dezen; Rocha, Talita Bueno; Bellesso, Marcelo; Teixeira, Larissa Lane Cardoso; Delamain, Marcia Torresan; Scheliga, Adriana Alves de Souza; Ribeiro, Glaciano Nogueira; Vaz Neto, Jorge; Baiocchi, Otávio Cesar Carvalho Guimarães; Abdo, André Neder Ramires; Arrais Rodrigues, Celso; Fogliatto, Laura M; Bigni, Ricardo de Sá; Schaffel, Rony; Biasoli, Irene; Pereira, Juliana; Nabhan, Samir Kanaan; Souza, Cármino Antônio de; Chiattone, Carlos Sérgio.
Hematol., Transfus. Cell Ther. (Impr.)
; 42(2): 103-110, Apr.-June 2020. ilus
Artículo
en Inglés
| LILACS | ID: biblio-1134022
ABSTRACT The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.
Biblioteca responsable:
BR408.1
Ubicación: BR408.1
Texto completo
Documentos relacionados